Do analysts rate SVA or OKUR?

OnKure Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 338.60%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 OnKure Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher valuation & earnings, SVA or OKUR?

OnKure Therapeutics has lower revenue, but higher earnings than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A

Is SVA or OKUR more profitable?

Sinovac Biotech's return on equity of 0.00% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A OnKure Therapeutics N/A -49.01% -45.77%

Is CBIO or OKUR more profitable?

OnKure Therapeutics' return on equity of -49.01% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Crescent Biopharma N/A -101.50% -86.86% OnKure Therapeutics N/A -49.01% -45.77%

Which has better valuation & earnings, OKUR or TECX?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.57 N/A

Is OKUR or TECX more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -49.01% -45.77% Tectonic Therapeutic N/A -35.26% -33.59%

Do analysts recommend AVTE or OKUR?

OnKure Therapeutics has a consensus target price of $17.50, indicating a potential upside of 338.60%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe OnKure Therapeutics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 OnKure Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher valuation and earnings, AVTE or OKUR?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A

Is AVTE or OKUR more profitable?

OnKure Therapeutics' return on equity of -49.01% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% OnKure Therapeutics N/A -49.01% -45.77%

OnKure Therapeutics (OKUR) Competitors

$3.99 +0.09 (+2.31%)

Closing price 04:00 PM Eastern

Extended Trading

$3.97 -0.02 (-0.50%)

As of 04:39 PM Eastern

Compare

OKUR vs. IRWD, SVA, CBIO, TECX, and AVTE

Should you buy OnKure Therapeutics stock or one of its competitors? OnKure Therapeutics's main competitors and comparable companies include Ironwood Pharmaceuticals (IRWD), Sinovac Biotech (SVA), Crescent Biopharma (CBIO), Tectonic Therapeutic (TECX), and Aerovate Therapeutics (AVTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does OnKure Therapeutics compare to Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

91.0% of OnKure Therapeutics shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of OnKure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ironwood Pharmaceuticals has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.40	$24.02M	$0.77	5.60
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

Ironwood Pharmaceuticals presently has a consensus target price of $6.23, indicating a potential upside of 44.62%. OnKure Therapeutics has a consensus target price of $17.50, indicating a potential upside of 338.60%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Ironwood Pharmaceuticals had 7 more articles in the media than OnKure Therapeutics. MarketBeat recorded 8 mentions for Ironwood Pharmaceuticals and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.87 beat Ironwood Pharmaceuticals' score of 0.85 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ironwood Pharmaceuticals	Positive
OnKure Therapeutics	Very Positive

Ironwood Pharmaceuticals has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to OnKure Therapeutics' net margin of 0.00%. OnKure Therapeutics' return on equity of -49.01% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
OnKure Therapeutics	N/A	-49.01%	-45.77%

Summary

Ironwood Pharmaceuticals beats OnKure Therapeutics on 10 of the 15 factors compared between the two stocks.

How does OnKure Therapeutics compare to Sinovac Biotech?

Sinovac Biotech (NASDAQ:SVA) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Sinovac Biotech had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 2 mentions for Sinovac Biotech and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.87 beat Sinovac Biotech's score of 0.93 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sinovac Biotech	Positive
OnKure Therapeutics	Very Positive

91.0% of OnKure Therapeutics shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by insiders. Comparatively, 2.2% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

OnKure Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 338.60%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Sinovac Biotech's return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
OnKure Therapeutics	N/A	-49.01%	-45.77%

OnKure Therapeutics has lower revenue, but higher earnings than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

Sinovac Biotech has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

Summary

Sinovac Biotech and OnKure Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does OnKure Therapeutics compare to Crescent Biopharma?

Crescent Biopharma (NASDAQ:CBIO) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by company insiders. Comparatively, 2.2% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

OnKure Therapeutics' return on equity of -49.01% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
OnKure Therapeutics	N/A	-49.01%	-45.77%

OnKure Therapeutics has lower revenue, but higher earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	58.73	-$153.94M	-$6.72	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

Crescent Biopharma currently has a consensus target price of $29.40, indicating a potential upside of 71.53%. OnKure Therapeutics has a consensus target price of $17.50, indicating a potential upside of 338.60%. Given OnKure Therapeutics' higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Crescent Biopharma has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

In the previous week, Crescent Biopharma had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 2 mentions for Crescent Biopharma and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.87 beat Crescent Biopharma's score of 0.79 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Crescent Biopharma	Positive
OnKure Therapeutics	Very Positive

Summary

OnKure Therapeutics beats Crescent Biopharma on 8 of the 14 factors compared between the two stocks.

How does OnKure Therapeutics compare to Tectonic Therapeutic?

OnKure Therapeutics (NASDAQ:OKUR) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Tectonic Therapeutic's return on equity of -35.26% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

OnKure Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.28, meaning that its share price is 228% more volatile than the broader market.

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

In the previous week, Tectonic Therapeutic had 7 more articles in the media than OnKure Therapeutics. MarketBeat recorded 8 mentions for Tectonic Therapeutic and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.87 beat Tectonic Therapeutic's score of 0.31 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
OnKure Therapeutics	Very Positive
Tectonic Therapeutic	Neutral

OnKure Therapeutics presently has a consensus price target of $17.50, indicating a potential upside of 338.60%. Tectonic Therapeutic has a consensus price target of $77.80, indicating a potential upside of 122.86%. Given OnKure Therapeutics' higher possible upside, research analysts plainly believe OnKure Therapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75

Summary

Tectonic Therapeutic beats OnKure Therapeutics on 8 of the 14 factors compared between the two stocks.

How does OnKure Therapeutics compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

91.0% of OnKure Therapeutics shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 2.2% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

OnKure Therapeutics' return on equity of -49.01% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
OnKure Therapeutics	N/A	-49.01%	-45.77%

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

In the previous week, OnKure Therapeutics had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for OnKure Therapeutics and 0 mentions for Aerovate Therapeutics. OnKure Therapeutics' average media sentiment score of 1.87 beat Aerovate Therapeutics' score of 0.00 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
OnKure Therapeutics	Very Positive

Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

OnKure Therapeutics has a consensus target price of $17.50, indicating a potential upside of 338.60%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe OnKure Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

OnKure Therapeutics beats Aerovate Therapeutics on 10 of the 13 factors compared between the two stocks.

Get OnKure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKUR vs. The Competition

Export

Metric	OnKure Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$157.54M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-1.14	10.67	269.06	25.28
Price / Sales	N/A	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.94	16.78	12.91	6.24
Net Income	-$59.52M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-3.62%	1.74%	1.12%	1.07%
1 Month Performance	-5.45%	1.60%	1.79%	1.03%
1 Year Performance	49.44%	56.43%	67.69%	20.77%

OnKure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKUR OnKure Therapeutics	3.1245 of 5 stars	$3.99 +2.3%	$17.50 +338.6%	+62.5%	$157.54M	N/A	N/A	N/A	Positive News Analyst Forecast
IRWD Ironwood Pharmaceuticals	3.1455 of 5 stars	$4.30 +6.2%	$6.23 +45.0%	+274.3%	$660.39M	$296.15M	5.58	220
SVA Sinovac Biotech	0.9343 of 5 stars	$6.47 flat	N/A	N/A	$644.66M	$386.01M	N/A	3,008	News Coverage High Trading Volume
CBIO Crescent Biopharma	3.1329 of 5 stars	$16.69 -3.7%	$29.40 +76.2%	+19.6%	$643.71M	$11.88M	N/A	50
TECX Tectonic Therapeutic	2.984 of 5 stars	$31.87 -2.6%	$77.80 +144.1%	+53.8%	$639.46M	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKUR) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OnKure Therapeutics (OKUR) Competitors

OKUR vs. IRWD, SVA, CBIO, TECX, and AVTE

How does OnKure Therapeutics compare to Ironwood Pharmaceuticals?

Summary

How does OnKure Therapeutics compare to Sinovac Biotech?

Summary

How does OnKure Therapeutics compare to Crescent Biopharma?

Summary

How does OnKure Therapeutics compare to Tectonic Therapeutic?

Summary

How does OnKure Therapeutics compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OnKure Therapeutics (OKUR) Competitors

OKUR vs. IRWD, SVA, CBIO, TECX, and AVTE

How does OnKure Therapeutics compare to Ironwood Pharmaceuticals?

Do insiders and institutionals believe in IRWD or OKUR?

Which has better valuation & earnings, IRWD or OKUR?

Do analysts recommend IRWD or OKUR?

Does the media favor IRWD or OKUR?

Which has more risk & volatility, IRWD or OKUR?

Is IRWD or OKUR more profitable?

Summary

How does OnKure Therapeutics compare to Sinovac Biotech?

Does the media favor SVA or OKUR?

Do institutionals and insiders hold more shares of SVA or OKUR?

Do analysts rate SVA or OKUR?

Is SVA or OKUR more profitable?

Which has higher valuation & earnings, SVA or OKUR?

Which has more volatility & risk, SVA or OKUR?

Summary

How does OnKure Therapeutics compare to Crescent Biopharma?

Do institutionals & insiders hold more shares of CBIO or OKUR?

Is CBIO or OKUR more profitable?

Which has preferable earnings and valuation, CBIO or OKUR?

Do analysts rate CBIO or OKUR?

Which has more volatility and risk, CBIO or OKUR?

Does the media favor CBIO or OKUR?

Summary

How does OnKure Therapeutics compare to Tectonic Therapeutic?

Is OKUR or TECX more profitable?

Which has more risk and volatility, OKUR or TECX?

Do insiders & institutionals believe in OKUR or TECX?

Which has better valuation & earnings, OKUR or TECX?

Does the media refer more to OKUR or TECX?

Do analysts prefer OKUR or TECX?

Summary

How does OnKure Therapeutics compare to Aerovate Therapeutics?

Do insiders & institutionals believe in AVTE or OKUR?

Is AVTE or OKUR more profitable?

Which has higher valuation and earnings, AVTE or OKUR?

Does the media favor AVTE or OKUR?

Which has more risk & volatility, AVTE or OKUR?

Do analysts recommend AVTE or OKUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools